MedPath

Effect of treatment with growth hormone in infertility”

Phase 3
Conditions
poor ovarian response.
Female infertility associated with anovulation
Registration Number
IRCT20140818018842N14
Lead Sponsor
Deputy of Research and Technology, Tehran University of Medical Sciences.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
105
Inclusion Criteria

Sign the informed consent form
Patients with poor ovarian response based on criteria provided by the Union embryology and infertility Europe 2011.
Strong history of poor ovarian response (Having a maximum of three ovum after inducing ovulation protocols)
Low score ovarian reserve (AFC less than 7, AMH less than 0.5-1.1 ng/ml)

Exclusion Criteria

Women with high levels of FSH (more than 20 IU/L)
Women with a history of infertility due to known non poor ovarian resonce
Women with diabetes (type I or II)

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The follicle number obtained in the ART cycle. Timepoint: Before starting treatment, on day eighth of a cycle, 36 hours after injecting HCG. Method of measurement: Trans vaginal ultrasonography.
Secondary Outcome Measures
NameTimeMethod
The number of metaphase II follicles achieved in the ART cycle. Timepoint: According embryologist report at ovum puncture. Method of measurement: Count of meta-phase II follicles in embryologist ward by microscopic observation.;The number of quality embryos obtained from the ART cycle. Timepoint: Third and fifth day after fertilization in the laboratory. Method of measurement: Report embryologists based grading A, B, C.;The number of positive pregnancy test. Timepoint: 14 days after embryo transfer. Method of measurement: BHCG over than 40 IU.;Successful clinical pregnancy. Timepoint: 6 to 8 weeks after embryo transfer. Method of measurement: Fetal Heart in Transvaginal ultrasonography.
© Copyright 2025. All Rights Reserved by MedPath